Rapid analysis of pharmacology for infectious diseases

Current Topics in Medicinal Chemistry

Volumn 11, Issue 10, 2011, Pages 1292-1300

  Hopkins, Andrew L ^a   Richard Bickerton, G ^a   Carruthers, Ian M ^a   Boyer, Stephen K ^b   Rubin, Harvey ^c   Overington, John P ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b IBM ALMADEN RESEARCH CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Chemogenomics; Druggable genome; Target identification

Indexed keywords

AMINO ACID; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADPH); GENE PRODUCT; PEPTIDE DEFORMYLASE INHIBITOR; PROTEIN; TRIMETHOPRIM;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; BRUGIA MALAYI; CHEMICAL STRUCTURE; CHEMOGENOMICS; CLINICAL RESEARCH; DRUG ACTIVITY; DRUG ANALYSIS; DRUG BINDING; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; FACTUAL DATABASE; GENE DELETION; GENE INACTIVATION; GENE SEQUENCE; GENE TARGETING; GENOME; GENOMICS; HIGH THROUGHPUT SCREENING; HYPOTHESIS; INFECTION; INFORMATION DISSEMINATION; KNOWLEDGE BASE; LEISHMANIA MAJOR; MEDICAL INFORMATICS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATENT; PLASMODIUM FALCIPARUM; POLYPHARMACOLOGY; PRACTICE GUIDELINE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN STRUCTURE; PROTEIN TARGETING; SCHISTOSOMA MANSONI; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; VACCINE PRODUCTION;

ANIMALS; COMMUNICABLE DISEASES; DRUG DESIGN; EPIDEMICS; GENOME; GENOMICS; HUMANS;

EID: 79959979886     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795429130     Document Type: Article

References (80)

1. Chan, M. Reaching the people left behind: A neglected success. In Prince Mahidol Award Conference, http://www.who.int/dg/speeches/2007/0102_thailand/en/index.html: Bangkok, 2007.
2. Trouiller, P.; Olliaro, P.; Torreele, E.; Orbinski, J.; Laing, R.; Ford, N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet, 2002, 359, 2188-2194.
3. Herrmann, D. J.; Peppard, W. J.; Ledeboer, N. A.; Theesfeld, M. L.; Weigelt, J. A.; Buechel, B. J. Linezolid for the treatment of drug-resistant infections. Exp. Rev. Anti Infect. Ther., 2008, 6, 825-848.
4. Projan, S. J.; Bradford, P. A. Late stage antibacterial drugs in the clinical pipeline. Curr. Opin. Microbiol., 2007, 10, 441-446.
5. Jones, K. E.; Patel, N. G.; Levy, M. A.; Storeygard, A.; Balk, D.; Gittleman, J. L.; Daszak, P. Global trends in emerging infectious diseases. Nature, 2008, 451, 990-993.
6. Hughes, B. 2007 FDA drug approvals: a year of flux. Nat. Rev. Drug Discov., 2008, 7, 107-109.
7. Hughes, B. 2008 FDA drug approvals. Nat. Rev. Drug Discov., 2009, 8, 93-96.
8. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov., 2007, 6, 29-40.
9. st World Health Assembly, Global strategy and plan of action on public health, innovation and intellectual property. In WHA61.21. 2008; Rule No. 11.6, pp 1-48.
10. Rubin, H.; Arroyo, A. The International Compact for Infectious Diseases; The Institute for Strategic Threat Analysis and Response, University of Pennsylvania: Philadelphia, 2007.
11. Rubin, H.; Rao, C. K. An enforceable international compact for infectious diseases: strategies to operationalize new initiatives to strengthen global health security. Curr. Sci., 2009, 96, 658-663.
12. Hopkins, A. L.; Witty, M. J.; Nwaka, S. Mission possible. Nature, 2007, 449, 166-169.
13. Agüero, F.; Al-Lazikani, B.; Aslett, M.; Berriman, M.; Buckner, F. S.; Campbell, R. K.; Carmona, S.; Carruthers, I. M.; Chan, A. W.; Chen, F.; Crowther, G. J.; Doyle, M. A.; Hertz-Fowler, C.; Hopkins, A. L.; McAllister, G.; Nwaka, S.; Overington, J. P.; Pain, A.; Paolini, G. V.; Pieper, U.; Ralph, S. A.; Riechers, A.; Roos, D. S.; Sali, A.; Shanmugam, D.; Suzuki, T.; Van Voorhis, W. C.; Verlinde, C. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug Discov., 2008, 7, 900-907.
14. Brass, A. L.; Dykxhoorn, D. M.; Benita, Y.; Yan, N.; Engelman, A.; Xavier, R. J.; Lieberman, J.; Elledge, S. J. Identification of host proteins required for HIV infection through a functional genomic screen. Science, 2008, 319, 921-926.
15. Krishnan, M. N.; Ng, A.; Sukumaran, B.; Gilfoy, F. D.; Uchil, P. D.; Sultana, H.; Brass, A. L.; Adametz, R.; Tsui, M.; Qian, F.; Montgomery, R. R.; Lev, S.; Mason, P. W.; Koski, R. A.; Elledge, S. J.; Xavier, R. J.; Agaisse, H.; Fikrig, E. RNA interference screen for human genes associated with West Nile virus infection. Nature, 2008, 455, 242-245.
16. Alksne, L. E.; Dunman, P. M. Target-based antimicrobial drug discovery. Methods Mol. Biol., 2008, 431, 271-83.
17. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1, 727-730.
18. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, A. C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol., 2007, 25, 71-75.
19. Al-Lazikani, B.; Gaulton, A.; Paolini, G.; Lanfear, J.; Overington, J.; Hopkins, A. In: The Molecular Basis of Predicting Druggability. Chemical Biology, Wess, G.; Schreiber, S., Eds. Wiley:USA. 2007.
20. Hopkins, A. L.; Groom, C. R. Target analysis: a priori assessment of druggability. Ernst Schering Res. Found. Workshop 2003, 42.
21. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem., 2005, 48, 2518-2525.
22. Russ, A. P.; Lampel, S. The Druggable Genome. Drug Discov. Today, 2005, 10, 23-24.
23. Kumar, S.; Chaudhary, K.; Foster, J. M.; Novelli, J. F.; Zhang, Y.; Wang, S.; Spiro, D.; Ghedin, E.; Carlow, C. K. Mining predicted essential genes of Brugia malayi for nematode drug targets. PLoS ONE, 2007, 2, e1189.
24. Balganesh, T. S.; Furr, B. J. Molecular approaches to target discovery:--evaluating targets for anti-tuberculosis drug discovery programmes. Infect. Disord. Drug Targets, 2007, 7, 120-126.
25. Hasan, S.; Daugelat, S.; Rao, P. S.; Schreiber, M. Prioritizing genomic drug targets in pathogens: application to mycobacterium tuberculosis. PLoS Comput. Biol., 2006, 2, e61.
26. Caffrey, C. R.; Rohwer, A.; Oellien, F.; Marhöfer, R. J.; Braschi, S.; Oliveira, G.; McKerrow, J. H.; Selzer, P. M. A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS ONE, 2009, 4, e4413.
27. Harris, C. J.; Stevens, A. P. Chemogenomics: structuring the drug discovery process to gene families. Drug Discov. Today, 2006, 11, 880-888.
28. Jacoby, E. Chemogenomics: Drug discovery's panacea? Mol. Biosyst., 2006, 2, 218-220.
29. Kubinyi, H. Chemogenomics in drug discovery. Ernst Schering Res. Found. Workshop. 2006, 58, 1-19.
30. Mestres, J. Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr. Opin. Drug Discov. Dev., 2004, 7, 304-313.
31. Paolini, G. V.; Shapland, R. H. B.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol., 2006, 24, 806-815.
32. Chen, F.; Mackey, A. J.; Vermunt, J. K.; Roos, D. S. Assessing performance of orthology detection strategies applied to eukaryotic genomes. PLoS ONE, 2007, 2, e383.
33. Thiele, I.; Jamshidi, N.; Fleming, R. M.; Palsson, B. Ø. Genomescale reconstruction of Escherichia coli's transcriptional and translational machinery: a knowledge base, its mathematical formulation, and its functional characterization. PLoS Comput. Biol., 5, e1000312.
34. Becker, S.; Feist, A.; Mo, M.; Hannum, G.; Palsson, B.; Herrgard, M. Quantitative prediction of cellular metabolism with constraintbased models: the COBRA Toolbox. Nat. Protoc., 2007, 2, 727-738.
35. Feist, A. M.; Herrgård, M. J.; Thiele, I.; Reed, J. L.; Palsson, B. Ø. Reconstruction of biochemical networks in microorganisms. Nat. Rev. Microbiol., 2009, 7, 129-143.
36. Feist, A. M.; Palsson, B. Ø. The growing scope of applications of genome-scale metabolic reconstructions using Escherichia coli. Nat. Biotechnol., 2008, 26, 659-667.
37. Feist, A. M.; Henry, C. S.; Reed, J. L.; Krummenacker, M.; Joyce, A. R.; Karp, P. D.; Broadbelt, L. J.; Hatzimanikatis, V.; Palsson, B. Ø. A genome-scale metabolic reconstruction for Escherichia coli K-12 MG1655 that accounts for 1260 ORFs and thermodynamic information. Mol. Syst. Biol., 2007, 3, 121.
38. Durot, M.; Bourguignon, P. Y.; Schachter, V. Genome-scale models of bacterial metabolism: reconstruction and applications. FEMS Microbiol. Rev., 2009, 33, 164-90.
39. Ortí, L.; Carbajo, R. J.; Pieper, U.; Eswar, N.; Maurer, S. M.; Rai, A. K.; Taylor, G.; Todd, M. H.; Pineda-Lucena, A.; Sali, A.; Marti-Renom, M. A. A kernel for open source drug discovery in tropical diseases. PLoS Negl. Trop. Dis., 2009 3, e418.
40. Pieper, U.; Eswar, N.; Davis, F.; Braberg, H.; Madhusudhan, M.; Rossi, A.; Marti-Renom, M.; Karchin, R.; Webb, B.; Eramian, D.; Shen, M.; Kelly, L.; Melo, F.; Sali, A. MODBASE: a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res., 2006, 34, D291-5.
41. Silver, L. L. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discov., 2007, 6, 41-45.
42. Brötz-Oesterhelt, H.; Brunner, N. A. How many modes of action should an antibiotic have? Curr. Opin. Pharmacol., 2008, 8(5), 564-573.
43. Bumann, D. Has nature already identified all useful antibacterial targets? Curr. Opin. Microbiol., 2008, 5, 387-392.
44. Denome, S. A.; Elf, P. K.; Henderson, T. A.; Nelson, D. E.; Young, K. D. Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis. J. Bacteriol., 1999, 181, 3981-3993.
45. Janoir, C.; Zeller, V.; Kitzis, M. D.; Moreau, N. J.; Gutmann, L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother., 1996, 40, 2760-2764.
46. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nature Chem. Biol., 2008, 4, 682-690.
47. Hillenmeyer, M. E.; Fung, E.; Wildenhain, J.; Pierce, S. E.; Hoon, S.; Lee, W.; Proctor, M.; St Onge, R. P.; Tyers, M.; Koller, D.; Altman, R. B.; Davis, R. W.; Nislow, C.; Giaever, G. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science, 2008, 320, 362-365.
48. Chait, R.; Craney, A.; Kishony, R. Antibiotic interactions that select against resistance. Nature, 2007, 446, 668-671.
49. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 2007, 25, 197-206.
50. Pullan, R.; Brooker, S. The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases? Parasitology, 2008, 135, 783-794.
51. Hopkins, A.; Lanfear, J.; Lipibski, C.; Beeley, L. Chemical tools for indications discovery. Ann. Rep. Med. Chem., 2005, 40, 339-348.
52. Thor, K. B.; Ashburn, T. T. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3, 673-683.
53. Tobinick, E. L. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect., 2009, 22, 119-125.
54. Pritchard, P. Capturing the Unexpected Benefits of Medical Research. Office of Health Economics: London, 2001.
55. Kell, D. B. Forces, Fluxes and the control of microbial growth and metabolism. The Twelfth Fleming Lecture. J. Gen. Microbiol., 1987, 133, 1651-1665.
56. Swanson, D. R. Medical literature as a potential source of new knowledge. Bull. Med. Libr. Assoc., 1990, 8, 29-37.
57. Loging, W.; Harland, L.; Williams-Jones, B. High-throughput electronic biology: mining information for drug discovery. Nat. Rev. Drug Discov., 2007, 6, 220-230.
58. Cokol, M.; Iossifov, I.; Weinreb, C.; Rzhetsky, A. Emergent behavior of growing knowledge about molecular interactions. Nat. Biotech., 2005, 23, 1243-1247.
59. Liu, C. I.; Liu, G. Y.; Song, Y.; Yin, F.; Hensler, M. E.; Jeng, W. Y.; Nizet, V.; Wang, A. H.; Oldfield, E. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science, 2008, 319(5868) 1391-1394.
60. Chen, X.; Chong, C. R.; Shi, L.; Yoshimoto, T.; Sullivan, D. J. J.; Liu, J. O. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc. Natl. Acad. Sci. USA, 2006, 103, 14548-14553.
61. Musonda, C. C.; Whitlock, G. A.; Witty, M. J.; Brun, R.; Kaiser, M. Synthesis and evaluation of 2-pyridyl pyrimidines with in vitro antiplasmodial and antileishmanial activity. Bioorg. Med. Chem. Lett., 2009, 19, 401-405.
62. Hajduk, P. J.; Huth, J. R.; Tse, C. Predicting protein druggability. Drug Discov. Today, 2005, 10, 1675-1682.
63. Seco, J.; Luque, F. J.; Barril, X. Binding site detection and druggability index from first principles. J. Med. Chem., 2009, 52, 2363-2371.
64. Halgren, T. A. Identifying and Characterizing Binding Sites and Assessing Druggability. J. Chem. Inf. Model., 2009, 49(2), 377-389.
65. Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res., 2006, 34, D668-D672.
66. Xia, X.; Maliski, E. G.; Gallant, P.; Rogers, D. Classification of kinase inhibitors using a Bayesian model. J. Med. Chem., 2004, 47, 4463-4470.
67. Bender, A.; Young, D. W.; Jenkins, J. L.; Serrano, M.; Mikhailov, D.; Clemons, P. A.; Davies, J. W. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb. Chem. High Throughput Screen., 2007, 10, 719-731.
68. Prathipati, P.; Ma, N. L.; Keller, T. H. Global Bayesian models for the prioritization of antitubercular agents. Chem. Inf. Model., 2008, 48(12), 2362-2370.
69. Hert, J.; Keiser, M.; Irwin, J.; Oprea, T.; Shoichet, B. Quantifying the relationships among drug classes. J. Chem. Inf. Model., 2008, 48, 755-765.
70. Gillet, V. J.; Willett, P.; Bradshaw, J. Similarity searching using reduced graphs. J. Chem. Inf. Comput. Sci., 2003, 43, 338-345.
71. Stiefl, N.; Watson, I. A.; Baumann, K.; Zaliani, A. ErG: 2D pharmacophore descriptions for scaffold hopping. J. Chem. Inf. Model., 2006, 46, 208-220.
72. Shoichet, B. K. Virtual screening of chemical libraries. Nature, 2004, 432, 862-865.
73. Ortí, L.; Carbajo, R. J.; Pieper, U.; Eswar, N.; Maurer, S. M.; Rai, A. K.; Taylor, G.; Todd, M. H.; Pineda-Lucena, A.; Sali, A.; Marti-Renom, M. A. A kernel for the Tropical Disease Initiative. Nature Biotechnol., 2009, 27, 320-321.
74. Swinney, D. C. Biochemical mechanism of drug action: what does it take for success? Nat. Rev. Drug Discov., 2004, 3, 801-808.
75. Swinney, D. C. Applications of Binding Kinetics to Drug Discovery: Translation of Binding Mechanisms to Clinically Differentiated Therapeutic Responses. Pharm. Med., 2008, 22, 23-34.
76. Palumbo, M. C.; Colosimo, A.; Giuliani, A.; Farina, L. Functional essentiality from topology features in metabolic networks: a case study in yeast. FEBS Lett., 2005, 579, 4642-4646.
77. Palumbo, M. C.; Colosimo, A.; Giuliani, A.; Farina, L. Essentiality is an emergent property of metabolic network wiring. FEBS Lett., 2007, 581, 2485-2489.
78. Fernandez-Garcia, M. D.; Mazzon, M.; Jacobs, M.; Amara, A. Pathogenesis of flavivirus infections: using and abusing the host cell. Cell Host Microbe., 2009, 5, 318-328.
79. Sessions, O. M.; Barrows, N. J.; Souza-Neto, J. A.; Robinson, T. J.; Hershey, C. L.; Rodgers, M. A.; Ramirez, J. L.; Dimopoulos, G.; Yang, P. L.; Pearson, J. L.; Garcia-Blanco, M. A. Discovery of insect and human dengue virus host factors. Nature, 2009, 458, 1047-1050.
80. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother., 2005, 49, 4721-4732.